Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.36 |
| ▸ | CA1 | P00915 | 13/20 | 0.36 |
| ▸ | CA9 | Q16790 | 8/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA7 | P43166 | 4/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.34 |
| ▸ | CA3 | P07451 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA6 | P23280 | 2/20 | 0.34 |
| ▸ | CA5A | P35218 | 2/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825362 | 0.84 | TSHR (0.36) | CA2CA1TSHRALDH1A1TP53 | |
| SCHEMBL11652838 | 0.82 | TSHR (0.34) | TSHRALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL88231 | 0.81 | TP53 (0.37) | CA2TSHRALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL368530 | 0.81 | TSHR (0.33) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL8458904 | 0.81 | MMP1 (0.35) | CA2CA1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL17542303 | 0.79 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL17542306 | 0.79 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL17542461 | 0.79 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL7125310 | 0.79 | MMP1 (0.34) | TSHRALDH1A1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL1646990 | 0.79 | TP53 (0.36) | CA2TSHRALDH1A1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518979-B2 | Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-08-27 | — | — | US | claimed |
| US-20100152254-A1 | ALPHA-HALO- AND ALPHA-ALKYL-CYCLOPROPYLCARBOXY COMPOUNDS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-06-17 | — | — | US | claimed |
| EP-2114864-A1 | ALPHA-HALO- AND ALPHA-ALKYL-CYCLOPROPYLCARBOXY COMPOUNDS AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (IL) | 2009-11-11 | — | — | EP | claimed |
| EP-1343807-B1 | DIARYL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITS C VIRUS | SCHERING CORP (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1268525-B1 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORP (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2008102348-A1 | ALPHA-HALO- AND ALPHA-ALKYL-CYCLOPROPYLCARBOXY COMPOUNDS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2008-08-28 | — | — | WO | claimed |
| US-8518979-B2 | Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-08-27 | — | — | US | disclosed |
| US-20100152254-A1 | ALPHA-HALO- AND ALPHA-ALKYL-CYCLOPROPYLCARBOXY COMPOUNDS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-06-17 | — | — | US | disclosed |
| EP-1725700-B1 | METHOD FOR REMOVING A COATING | OERLIKON TRADING AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| EP-2114864-A1 | ALPHA-HALO- AND ALPHA-ALKYL-CYCLOPROPYLCARBOXY COMPOUNDS AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (IL) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008102348-A1 | ALPHA-HALO- AND ALPHA-ALKYL-CYCLOPROPYLCARBOXY COMPOUNDS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2008-08-28 | — | — | WO | disclosed |
| EP-1725700-A1 | METHOD FOR REMOVING A COATING AND SINGLE-CHAMBER DEVICE FOR CARRYING OUT SAID METHOD | OC Oerlikon Balzers AG (LI) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005073433-A1 | METHOD FOR REMOVING A COATING AND SINGLE-CHAMBER DEVICE FOR CARRYING OUT SAID METHOD | UNAXIS BALZERS AG (LI) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152254-A1 | ALPHA-HALO- AND ALPHA-ALKYL-CYCLOPROPYLCARBOXY COMPOUNDS AND USES THEREOF | INA, GBA1, SCN1A | CA2 514/4885CA1 131/4885CA9 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.